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 SUMMARY 
PTPRB is a transmembrane protein tyrosine phosphatase known to regulate blood vessel 
remodelling and angiogenesis. Here we demonstrate that PTPRB negatively regulates 
branching morphogenesis in the mammary epithelium. We show that Ptprb is highly expressed 
in adult mammary stem cells and also, although at lower levels, in estrogen receptor positive 
luminal cells. During mammary development Ptprb expression is down-regulated during 
puberty, a period of extensive of ductal outgrowth and branching. In vivo shRNA knockdown 
of Ptprb in the cleared mammary fat pad transplant assay resulted in smaller epithelial 
outgrowths with an increased branching density and also increased branching in an in vitro 
organoid assay. Organoid branching was dependent on stimulation by FGF2, and Ptprb 
knockdown in mammary epithelial cells resulted in a higher level of FGFR activation and 
ERK1/2 phosphorylation, both at baseline and following FGF2 stimulation. Therefore, PTPRB 
regulates branching morphogenesis in the mammary epithelium by modulating the response of 
the FGFR signalling pathway to FGF stimulation. Considering the importance of branching 
morphogenesis in multiple taxa, our findings have general importance outside mammary 
developmental biology.  
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 INTRODUCTION 
The mammary gland is a highly dynamic organ; limited embryonic development is followed 
by extensive postnatal pubertal development with further differentiation and tissue remodelling 
occurring during pregnancy and lactation (Macias and Hinck, 2012). A key aspect of mammary 
epithelial structure formation is branching morphogenesis, a patterning event driven by 
systemic and local cues (Sternlicht, 2006). During pubertal development, branching 
morphogenesis is dependent on the balance between the rate of ductal extension driven by 
Terminal End Buds (TEBs; specialised growth structures at the tips of the developing ducts), 
the rate of TEB bifurcation and, in the later stages of development, the formation of lateral 
branches from established ducts. As branching morphogenesis is a common developmental 
process in many tissues in many taxa, understanding its regulation in the mammary gland can 
have implications beyond a single system and can inform paradigms of development across the 
animal kingdom. 
 
The growth of TEBs, and thus of the subtending ducts, is driven by one or more stem cell 
population(s) which generate the two main mammary epithelial lineages (‘basal’ and ‘luminal’) 
during puberty (Ball, 1998; Srinivasan et al., 2003; Williams and Daniel, 1983). Stem cells 
dispersed throughout the mature mammary epithelium are also thought to be important for 
maintenance of the adult non-pregnant gland, although the nature of these remains 
controversial (Rios et al., 2014; Van Keymeulen et al., 2011; Wang et al., 2015). It is clear, 
however, that the basal layer contains a small population of cells with potent outgrowth 
potential in mammary fat pad transplant experiments and which upon transplantation 
regenerate complete basal and luminal layers, consistent with a stem cell identity (Shackleton 
et al., 2006; Sleeman et al., 2006; Stingl et al., 2006). In addition to this transplantable stem 
cell population, the basal layer consists mainly of contractile myoepithelial cells. The luminal 
layer consists of populations of progenitors (Regan et al., 2012) as well as functionally 
differentiated cells, including hormone-sensing ER positive (ER+) cells and the secretory ER 
negative (ER-) cells found in the alveoli during lactation. The luminal progenitors are mainly 
ER- (Regan et al., 2012). The molecular regulation of epithelial homeostasis in these stem-
progenitor-differentiated populations, and how this homeostasis contributes to tissue 
morphogenesis, remains an area of intense interest. 
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 PTPRB, also known as RPTP and VE-PTP, is a highly promiscuous R3 type receptor protein 
tyrosine phosphatase which can dephosphorylate multiple receptor tyrosine kinases (Barr et al., 
2009). It consists of a single intracellular catalytic domain with C-terminal phosphorylation 
sites, a transmembrane domain and an extracellular domain with multiple fibronection type III-
like domains (Matozaki et al., 2010). Binding by heparin binding domain-containing growth 
factors, such as pleiotropin, cause dimerization and inactivation (Maeda and Noda, 1998). The 
role and functions of PTPRB have been most fully described in the development of the 
embryonic vasculature (Baumer et al., 2006; Dominguez et al., 2007) and in arterial endothelial 
cells, in which the two main targets of PTPRB have been identified as the receptor tyrosine 
phosphatase TEK and vascular endothelial cadherin / cadherin 5 (VE-cadherin / CDH5). 
PTPRB activity enhances VE-cadherin-mediated adhesion (Nawroth et al., 2002) but is a 
negative regulator of TEK (Baumer et al., 2006; Dominguez et al., 2007). 
 
We recently identified a set of 323 genes, including Ptprb, whose expression was specifically 
associated with the transplantable basal mammary stem cell (MaSC) population in the adult 
mouse mammary epithelium (Soady et al., 2015). As a regulator of morphogenesis in other 
systems, we hypothesised that PTPRB may also be a regulator of mammary development. 
However, owing to the embryonic lethality of Ptprb gene ablation and the lack of a conditional 
knockout model, the functional role of PTPRB in postnatal mammary gland development has 
not previously been studied. We have therefore exploited the potential of cleared fat pad 
transplantation in an in vivo functional genomics approach as well as in vitro mechanistic 
studies to determine whether PTPRB is required for normal mammary morphogenesis. We find 
that PTPRB is a negative regulator of branching morphogenesis, acting by modulating 
signalling downstream of FGFR. These results have general importance for understanding the 
regulation of epithelial branching morphogenesis. 
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 RESULTS 
Expression patterns of Ptprb in the mammary epithelium alter during postnatal 
mammary development 
In an Affymetrix microarray-based analysis of gene expression in the adult (10-12 week old) 
mammary epithelium comparing highly purified MaSCs with the other major epithelial 
subpopulations (myoepithelial cells, luminal ER- progenitors and luminal ER+ differentiated 
cells) we identified a 323 MaSC gene signature that included Ptprb (Soady et al., 2015). We 
hypothesised that PTPRB may be a regulator of mammary morphogenesis. 
 
To test this hypothesis, we evaluated Ptprb expression by quantitative real-time reverse 
transcriptase PCR (qPCR) during post-natal mammary gland development in highly purified 
primary mammary epithelium subpopulations isolated by flow cytometry at three 
developmental time-points. MaSCs, myoepithelial (MYOs), luminal ER- progenitors (LumER-
) and luminal ER+ differentiated (LumER+) cells were isolated from female FVBn mice as 
previously described (Regan et al., 2012; Soady et al., 2015) (supplementary material Fig.S1). 
The developmental stages assessed covered pubertal mammary gland morphogenesis with 
three time points representing the onset/early stages of pubertal development (3-4 weeks), mid-
puberty (5-6 weeks) and late puberty/young adulthood (8-10 weeks) (Fig.1A). 
 
Comparison of expression levels between the populations at each timepoint (Fig.1B) 
demonstrated that at onset of puberty Ptprb was more highly expressed in LumER+ cells than 
in MaSCs (P≤0.01). At mid-puberty, when the majority of ductal outgrowth occurs, Ptprb 
expression was not significantly different between the MaSCs and LumER+ populations. 
Confirming our previous findings from the adult gland (Soady et al., 2015), at 8-10 weeks 
Ptprb was most highly expressed (P≤0.01) in MaSCs. However, at all timepoints, both MaSCs 
and LumER+ cells had significantly higher levels of Ptprb expression than the LumER- and 
MYO populations. 
 
Comparing expression levels between the time points within each cell subpopulation (Fig.1C) 
showed that for each population Ptprb expression was reduced at 5-6 weeks (the period of most 
extensive epithelial expansion and morphogenesis) compared with expression levels at 3-4 
weeks (P≤0.05 for LumER- cells, P≤0.01 for MYOs, MaSCs and LumER+ cells). By 8-10 
weeks, Ptprb expression in MaSCs had returned to 3-4 week levels; however, for the LumER+ 
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 and MYOs, although Ptprb expression levels were increased compared with 5-6 week levels, 
they remained significantly lower than at 3-4 weeks old (P≤0.01 for both populations). 
 
Consistent with the qPCR expression analysis, and the known role of PTPRB in endothelial 
cells, RNAScope in situ hybidisation localised Ptprb to the endothelial cells of blood vessels 
in the 3-week old mammary gland and to a subset of luminal epithelial cells in mammary ducts 
(supplementary material Fig.S2). In the 6-week old gland, Ptprb expression could not be 
detected in the mammary epithelium, either because the numbers of cells expressing was very 
low, or, the expression level per cell had fallen below the threshold for detection by the 
technique. However, at this time Ptprb was expressed in a group of stromal cells surrounding 
the ducts. Finally, at 12 weeks Ptprb was again detected in a subset of luminal cells although 
at much weaker levels (supplementary material Fig.S2), consistent with the qPCR. We did not 
observe basal cells with a Ptprb signal at any age, however, basal mammary stem cells are very 
rare and indeed have never been definitively identified in histological sections, so this is not 
surprising. 
 
As Pptrb expression was below the limits of detection by in situ hybridisation at 6 weeks, to 
determine whether Ptprb was differentially expressed in the two main morphological structures 
of the developing gland, the TEBs and their subtending ducts, a gene expression profile data 
set of microdissected TEBs compared with ducts collected at 6 – 7 weeks was mined for Ptprb 
expression (supplementary material Table S1). This analysis demonstrated that Prprb is 
expressed at significantly lower levels in the TEBs compared to the ducts (1.5-fold lower; 
P<0.05). 
 
In summary, Ptprb is most highly expressed in MaSCs and LumER+ cells in the adult 
mammary epithelium, but its expression pattern is dynamically regulated during pubertal 
development. LumER+ cells have a decrease in Ptprb expression at mid-puberty followed by 
a partial recovery; MaSCs also have a decrease in mid-puberty but a strong recovery in the 
adult tissue back to levels seen at pubertal onset. During puberty, Ptprb is expressed at lower 
levels in TEBs than in ducts. The strong recovery of expression in MaSCs compared with the 
partial recovery in LumER+ cells results in the MaSCs becoming the highest expressers of 
Ptprb in the adult gland. 
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 Ptprb knockdown promotes branching morphogenesis in vivo 
The correlation between lower levels of Ptprb expression and the period of most intense 
morphogenetic activity in the mammary gland, suggested that PTPRB may be a negative 
regulator of mammary morphogenesis. We tested this in in vivo functional assays. In the first 
series of experiments, primary mouse mammary epithelial cells were transduced in short term 
culture (48 hour) with either a pooled lentiviral supernatant containing two shRNA sequences 
against Ptprb (shPtprb pool consisting of shPtprb 0145 plus shPtprb 3820) or a control shRNA 
designed to target luciferase (shLuc). In a second series of three independent experiments, 
primary cells were transduced in short term culture with one of two different lentiviral 
constructs carrying shRNA sequences targeting Ptprb (shPtprb 0145 or shPtprb 3820) or with 
a lentvirus carrying a scrambled sequence (shScr). In both sets of experiments the viral vectors 
also contained GFP to mark transduced cells and supernatants were diluted to ensure both 
control and shPtprb supernatants contained equal viral titres. The efficacy of the shPtprb pool 
and the individual lentiviruses in suppressing Ptprb expression was confirmed by qPCR 
(Fig.2A,B). Transduced cells were transplanted into cleared mammary fat pads at 50,000 cells 
per fat pad. At eight weeks, fat pads were harvested and examined under epifluorescent 
illumination, after which they were processed for flow cytometric analysis to assess relative 
proportions of the epithelial cell populations.  
 
There were no differences in the number of successful outgrowths between the shLuc (8 
outgrowths from 11 transplanted fat pads; n = two independent experiments) and the shPtprb 
pool (11/11; n = two independent experiments) transplants or between the shScr (23/24; n = 
three independent experiments), the shPtprb 0145 (13/13; n = three independent experiments) 
and the shPtprb 3820 (11/13; n = three independent experiments) transplants. However, Ptprb-
knockdown transplants appeared to be more densely branched but filled less of the total area 
of the fat pad than the control outgrowths (Fig.2C). Quantitation of the area of the outgrowths 
and of the number of branch points per mm2 confirmed that knockdown outgrowths were 
significantly smaller than control outgrowths but more densely branched (Fig.2D,E). 
 
Both control and Ptprb-knockdown outgrowths had distinct luminal (keratin 18, K18, positive) 
and basal/myoepithelial (smooth muscle actin, SMA, positive) layers (Fig.3A). Flow 
cytometric analysis of the outgrowths confirmed that there were no differences in the 
proportions of the major epithelial populations (supplementary material Fig.S3). Ki67 staining 
of control and Ptprb-knockdown transplants demonstrated that, at the time point at which the 
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 transplants were harvested, there was little or no proliferation in control tissue but Ptprb-
knockdown tissue was highly proliferative (Fig.3B). However, the smaller size and denser 
branching of the knockdown tissue (meaning that sections were more likely to be enriched for 
the TEBs) is an important caveat in this analysis. In the proliferating Ptprb-knockdown tissue, 
equivalent numbers of Ki67 positive cells were observed in SMA positive basal and SMA 
negative luminal layers (Fig.3B,C). Little or no cleaved caspase-3, a marker of apoptosis, could 
be detected in either control or Ptprb-knockdown outgrowths (supplementary material 
Fig.S4B). 
 
To determine whether Ptprb knockdown perturbed stem cell function as assessed by 
engraftment potential, GFP-positive regions from a series of successful shScr and shPtprb 0145 
primary transplants were dissected out, digested to single cells and then retransplanted. Take 
rates for secondary transplantation into contralateral fat pads of shScr and shPtprb 0145 
transduced cells were 8/9 for both the control and knockdown cells. Consistent with the primary 
transplants, shPtprb 0145-transduced outgrowths had a significantly smaller area than control 
outgrowths (Fig.3D and supplementary material Fig.S4C). Overall, these findings show 
PTPRB does not affect stem cell engraftment potential or lineage determination, but does 
regulate mammary branching morphogenesis. 
 
Ptprb knockdown promotes branching morphogenesis in an in vitro model system in an 
FGF-dependent manner 
To provide further support for a role for PTPRB in regulating branching morphogenesis and to 
establish a model in which mechanism of action of PTPRB could be addressed, we utilised an 
in vitro branching morphogenesis assay (Ewald et al., 2008). Small fragments of mammary 
epithelial ducts which retain the basal-luminal bilayered architecture (‘organoids’) were either 
left untransduced or transduced with Scr, shPtprb 0145 or shPtprb 3820 lentiviruses, embedded 
in Matrigel and treated for five days with medium containing FGF2, which stimulates 
branching in this system (Ewald et al., 2008). The total number of organoids and number of 
branched organoids were counted; branched organoids were defined as an organoid with at 
least one branch protruding from the main spherical body.  
 
Organoid cultures branched only in the presence of FGF2; in the absence of FGF2, Ptprb 
knockdown alone was not sufficient to stimulate branching (supplementary material Fig.S5A). 
However, knockdown of Ptprb in FGF2-stimulated cultures significantly increased (P≤0.05) 
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 the number of branched organoids, with 40% of organoids branching in non-infected and Scr 
controls to >60% in shPtprb1 0145 and shPtprb2 3820 cultures (Fig.4A). The amount of 
branching in non-infected and Scr controls was consistent with previous reports on branching 
in unmanipulated primary mammary epithelial organoids (Macias et al., 2011). Therefore, 
Ptprb knockdown in vitro increased the number of organoids competent to branch under FGF2 
stimulation.  
 
To assess whether Ptprb knockdown also affected the extent of branching, the degree of 
branching in all branched organoids was ascertained. Branched organoids were catergorised 
into low (1-5 branches), intermediate (6-15 branches) or highly branched (>15 branches) 
organoids (Fig.4B,C). Compared with control cultures, shPtprb 0145 and shPtprb 3820-
transduced organoids had an increase in the proportion of highly branched organoids and a 
reduction in numbers of organoids with low branching levels (Fig.4C). Therefore, in vitro 
knockdown of Ptprb increased both the percentage of branched mammary epithelial organoids 
and the number of branches on each branched organoid, but only under conditions of growth 
factor stimulation. 
 
Endogenous Ptprb expression is downregulated during in vitro branching morphogenesis 
In vivo, levels of endogenous Ptprb expression were suppressed during the period of post-natal 
mammary development. To determine if similar changes in Ptprb expression occur during 
organoid branching in vitro, and to characterise in more detail the relationship between the 
kinetics of endogenous Ptprb expression and branching, unmanipulated non-infected organoids 
were embedded in Matrigel and stimulated with or cultured without FGF2 for 6 days. Non-
stimulated organoids did not grow or branch over the experimental time course whereas 
stimulated organoids expanded in size and produced branches, with the first obvious branching 
apparent by day 4 (Fig.5A). qPCR analysis of Ptprb expression in FGF2-stimulated branching 
organoids showed that Ptprb expression was reduced over time in stimulated organoids relative 
to day 0. The reduction in Ptprb expression was significant from day 1, decreased further at 
day 3 and remained low until the end of the time course (Fig.5B). 
 
To control for the possibility that the decrease in Ptprb expression was related to the time in 
culture rather than correlated with FGF2 stimulation and concomitant branching, levels of 
Ptprb expression in stimulated organoids were compared to non-stimulated organoids at each 
time point (Fig.5C). This demonstrated that Ptprb expression in stimulated organoids was 
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 significantly lower than in non-stimulated organoids by day 3 and continued to drop at days 4 
and 5. Importantly, these findings showed that the first significant difference between Ptprb 
levels in non-stimulated and stimulated organoids was seen just before (day 3) the stimulated 
organoids initiated branching (day 4). This suggests a temporal correlation between FGF2 
stimulation, Ptprb expression and branching. 
 
PTPRB acts on FGFR – ERK1/2 signalling to inhibit mammary branching 
morphogenesis 
The in vivo and in vitro findings, taken together, suggested that while PTPRB does not directly 
inhibit mammary morphogenesis, it acts as a negative regulator of signalling pathways that 
promote branching morphogenesis. In this model, suppression of Ptprb expression would result 
in either a higher or more sustained level of signalling by pro-branching pathways. The 
organoid culture system had already demonstrated that PTPRB expression interacted with FGF 
signalling in vitro. To determine whether there was evidence for an interaction between PTPRB 
and FGF signalling in vivo, and to assess the possibility that PTPRB may regulate other 
signalling pathways associated with mammary branching morphogenesis, we used qPCR to 
examine the expression of three receptor tyrosine kinases (Erbb2, Egfr and Tek) previously 
suggested to interact with PTPRB and with potential roles in mammary branching 
morphogenesis (Andrechek et al., 2005; Chodosh et al., 2000; Wiesen et al., 1999). We also 
examined expression of three receptor kinases, including two members of the FGF receptor 
family (Fgfr1, Fgfr2 and Igfr1), not previously described as interacting with PTPRB but known 
to play an important role in mammary development (Lu et al., 2008; Pond et al., 2013; 
Sternlicht et al., 2006). Patterns of expression in the different mammary epithelial 
subpopulations at the 5-6 week developmental time point (when branching morphogenesis in 
the mammary epithelium is maximal) were determined and compared with the previously 
established pattern of Ptprb expression (Fig.6A). This analysis showed a strong correlation 
between Ptprb expression and the patterns of Fgfr2 and Tek expression across the 
subpopulations, but no correlation with Egfr, Fgfr1 or Igfr1 expression. 
 
Next, expression of Fgfr2 and Tek across, the 3-4 week, 5-6 week and 8-10 week time course 
was examined and compared with Ptprb (Fig. 6B,C). We concentrated on expression patterns 
in the MaSCs and LumER+ cells, as these two populations showed the highest levels of Ptprb, 
Fgfr2 and Tek at 5–6 weeks. Expression of Tek in LumER+ cells was significantly lowered in 
5-6 week animals relative to 3- 4 weeks. However, by 8-10 weeks it was back to 3-4 week 
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 levels (Fig.6B). By contrast, Tek levels in MaSCs were not significantly different between 3-4 
weeks and 5-6 weeks and then fell significantly at 8-10 weeks. Thus, there were similarities 
between Tek and Ptprb expression patterns in LumER+ cells, although these were not exact. 
However, there were no obvious correlations between Tek and Ptprb expression in MaSCs 
(Fig.6C). 
 
Fgfr2 expression levels were not significantly different in the LumER+ cells between 3 – 4 
weeks and 5 – 6 weeks but were significantly increased at 8 – 10 weeks. However, in MaSCs, 
there was a significant increase in Fgfr2 expression at 5 – 6 weeks over 3 – 4 weeks, and then 
a decrease in expression. Therefore, there was no obvious correlation between Ptprb and Fgfr2 
expression in LumER+ cells but there was an inverse correlation between the Ptprb and Fgfr2 
expression patterns in the MaSCs (Fig.6B,C). 
 
The in vitro organoid assay had already demonstrated that treatment with the FGFR ligand 
FGF2 promotes branching morphogenesis whilst suppressing Ptprb expression, supporting the 
inverse correlative relationship between Fgfr2 and Ptprb expression in vivo. We now tested 
whether two ligands for TEK, Angiopoietin1 and 2 (ANG1 and 2) could substitute for FGF2 
in this assay. However, neither was able to stimulate branching (supplementary material 
Fig.S5B), suggesting the ANG-TEK axis is not involved in mammary branching 
morphogenesis. We therefore focussed on FGFR signalling and addressed whether PTPRB is 
a negative regulator of this pathway.  
 
As PTPRB is a cell surface receptor phosphatase, we hypothesised that it may be regulating 
phosphorylation of FGF receptors. We therefore tested in three independent experiments 
whether Ptprb knockdown altered baseline levels of FGFR phosphorylation as well as the 
response to FGF2. Indeed, transduction with the shPtprb 3820 virus significantly increased 
FGFR phosphorylation over shLuc control, both baseline levels and in response to FGF2. The 
effects of shPtprb 0145 were more modest, with a significant difference only seen after five 
minutes of FGF2 treatment (Fig. 7A and supplementary material Fig. S6). Note that pFGFR 
antibodies cannot distinguish among the FGFR receptor isoforms, so it is not possible to 
determine which (or indeed if more than one) of the family shows increased phosphorylation 
in response to Ptprb knockdown. However, by using non-phospho-specific antibodies which 
do distinguish between the isoforms, we were able to demonstrate that total levels of FGFR1, 
2, 3 and 4 were not changed when Ptprb was knocked down (supplementary material Fig.S7 
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 and S8), confirming that the increase in pFGFR levels was indeed due to increased receptor 
phosphorylation not due to increased receptor expression. 
 
We next tested whether Ptprb knockdown altered the response of a downstream effector of 
FGF signalling, ERK1/2, to FGF2. First, we confirmed that branching in the organoid culture 
system in response to FGF2 was dependent on ERK1/2 activity, using a small molecule 
inhibitor of ERK (SCH772984; supplementary material Fig.S9 and Fig.S10). Next, organoids 
cultured in the in vitro branching assay system were transduced with either shLuc, shPtprb 
0145 or shPtprb 3820 knockdown virus and protein lysates collected either from unstimulated 
cultures or from cultures after 5, 15 and 60 minutes of FGF2 stimulation. In three independent 
experiments, Ptprb knockdown by both shPtprb 0145 and shPtprb 3820 resulted in a 
statistically significant increase in unstimulated baseline ERK1/2 phosphorylation compared 
with shLuc controls. In response to FGF2 stimulation, shPtprb 3820 cultures continued to show 
statistically significantly higher levels of phosphorylation at all time points, over and above the 
increased phosphorylation resulting from activation of the pathway. shPtprb 0145 cultures also 
showed higher mean phosphorylation but the differences in stimulated cultures were not 
statistically significant (Fig.7B and supplementary material Fig.S11). 
 
Finally, FGF-stimulated organoids in which Ptprb had been knocked-down by either shPtprb 
0145 or shPtprb 3820, were treated with SCH772984. In control cultures, knockdown 
organoids showed increased branching in response to FGF, as previously. However, treatment 
with the inhibitor partially restored branching back to control levels in shPtprb 0145-transduced 
cultures and fully restored control branching levels in shPtprb 3820 cultures (Fig. 7C). Taken 
together, these findings support the model that PTPRB suppresses branching morphogenesis 
via inhibition of the FGFR2 – ERK1/2 signalling axis. 
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 DISCUSSION 
Mammary epithelial development is a highly regulated process dependent on the interplay 
between systemically acting hormones and locally produced growth factors. During puberty 
rising levels of the ovarian steroid hormones oestrogen and progesterone, growth hormone 
secreted from the pituitary gland and locally produced growth factors cause a significant 
increase in ductal growth (Hennighausen and Robinson, 2001; Macias and Hinck, 2012). This 
growth is driven by bulbous TEBs, which form at the tips of elongating primary ducts and 
regularly bifurcate to form the primary branches of the ductal epithelium. As the mammary 
tree matures, secondary side branches sprout laterally at regular intervals, from which will form 
the tertiary lateral branches that occur at each diestrus and during pregnancy. The TEB-tipped 
ducts grow until they reach the edge of the fat pad. At this stage, the TEBs regress and the 
subtending duct becomes relatively quiescent, leaving the branched ductal structures of the 
mature virgin gland (Hens and Wysolmerski, 2005). The unique “open architecture” of the 
non-pregnant gland suggests that branching morphogenesis is a highly regulated process, 
involving orchestrated ductal elongation, TEB bifurcation and lateral branching, which ensures 
space for additional proliferation and the formation of alveoli during pregnancy. A number of 
positive regulators of this process have been reported, such as the estrogen – estrogen receptor 
alpha (ER) axis and its downstream effectors, the growth hormone – growth hormone receptor 
– insulin-like growth factor 1 axis, epidermal growth factor receptor (EGFR) signalling and 
fibroblast growth factor receptor (FGFR) signalling. However, few negative regulators have 
been identified, Transforming growth factor beta 1 (TGFB1) and Sprouty 2 (SPRY2) being 
notable exceptions (Sternlicht, 2006; Sternlicht et al., 2006). Here, we have now identified 
PTPRB as a novel negative regulator of this process. 
 
In arterial endothelial cells, PTPRB activity enhances VE-cadherin-mediated adhesion 
(Nawroth et al., 2002) but is a negative regulator of TEK. Use of PTPRB inactivating 
antibodies in adult mice triggered activation of TEK, resulting in increased downstream 
signalling via ERK1/2 which in turn caused increased endothelial cell proliferation and 
enlargement of vascular structures (Winderlich et al., 2009). Thus, PTPRB is required to 
balance TEK activity and endothelial cell proliferation, thereby controlling blood vessel 
development and vessel size. This is supported by work in two independent germline Ptprb 
mouse knockout models, in which embryonic lethality occurred at around 10 days gestation 
due to severe vascular defects. In both models, vasculogenesis occurred normally but 
angiogenesis was severely affected leading to the deterioration of the intraembryonic vascular 
D
ev
el
o
pm
en
t •
 A
cc
ep
te
d 
m
an
us
cr
ip
t
 system and lethality, demonstrating an essential role for PTPRB in angiogenesis and blood 
vessel remodelling (Baumer et al., 2006; Dominguez et al., 2007). 
 
In contrast to angiogenesis, in the mammary epithelium we find that PTPRB regulates 
morphogenesis by modulating FGFR signalling rather than TEK signalling. FGFRs can 
activate a number of potential downstream pathways, including PI3K/PIP2/AKT, 
PLC/IP3/Ca2+/Calmodulin and SOS/RAS/RAF/MEK/ERK. FGFR stimulates the 
SOS/RAS/RAF/MEK/ERK pathway by phosphorylation of Fibroblast Growth Factor Receptor 
Substrate 2 (FRS2), which in turn recruits GRB2, activating SOS and the downstream cascade 
(Katoh, 2009). Notably, SPRY2, another negative regulator of branching morphogenesis 
(Sternlicht, 2006; Sternlicht et al., 2006) is a negative regulator of FGF-induced ERK-pathway 
activation (Rubin et al., 2005), likely acting downstream of the GRB2-SOS complex (Gross et 
al., 2001). Here, we have demonstrated that knockdown of PTPRB results in higher baseline 
levels FGFR phosphorylation, resulting in higher levels of downstream p-ERK1/2 and a more 
sustained response to FGF2 stimulation, leading to a more densely  branched mammary tree. 
 
Evidence is emerging that PTPRB may be a tumour suppressor gene in a variety of cancers. 
Recurrent PTPRB loss-of-function mutations have been identified in angiosarcoma (in 10 of 
39 tumours examined) (Behjati et al., 2014), consistent with its normal role in angiogenesis, 
but also in metastatic melanoma (9 tumours with missense, nonsense or splice-site mutations 
out of a 97 tumour set) (Ding et al., 2014). Homozygous single nucleotide variations in PTPRB 
have also been reported in a rare family with siblings with glioblastoma multiforme; the parents 
were heterozygous for the mutations (Backes et al., 2014). No specific study of PTPRB in 
breast cancer has been undertaken, although Ptprb is a component of the MaSC gene signature 
we have identified as being prognostic in breast tumours (Soady et al., 2015). In contrast, a link 
between FGFR2 and breast cancer is well-established. FGFR2 gene amplification and FGFR2 
protein overexpression (especially of C-terminally truncated products) occurs in primary ER+ 
breast cancer (Adnane et al., 1991; Katoh, 2003). The C-terminally truncated product can 
activate signalling cascades in a ligand-independent manner (Moffa and Ethier, 2007). 
Missense point mutations also occur in primary breast cancer (Stephens et al., 2005) and SNPs 
in intron2 of FGFR2 are associated with an increased risk of ER+ breast cancer (Easton et al., 
2007). Our findings suggest FGFR2 and PTPRB should be considered as part of an integrated 
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 signalling pathway when assessing the activity of receptor tyrosine kinase signalling cascades 
in breast cancer. 
 
Our study does have limitations, including potential off-target and non-specific toxic effects of 
shRNA, as well as potential variable levels of viral infection and variable tropisms to different 
cell types. To offset the issue of infection levels, we chose a minimum cut-off of 30% GFP-
positive cells for analysis of organoids based on previously published work (Macias et al., 
2011). Furthermore, the pattern of expression of FGF receptors in organoid cultures is unknown 
and any period of culture may alter the behaviour of epithelial cell subtypes compared with the 
in vivo situation. Nevertheless, the results of the study as a whole are consistent in supporting 
a role for PTPRB in regulating FGF-dependent branching morphogenesis. 
 
We cannot definitively distinguish between a role for PTPRB in TEB bifurcation, ductal 
elongation or lateral branching. However, the increased density of branching shown in Ptprb 
transplant outgrowths must have resulted from either a decrease in the rate of ductal elongation 
or an increase in the rate of formation of new branch points (either by TEB bifurcation or lateral 
branching). Ptprb knockdown resulting in a decrease in ductal elongation would not be 
consistent with our in vitro findings that Ptprb-knockdown organoids have more branches in 
response to FGF treatment. Furthermore, higher expression of Ptprb in subtending ducts 
relative to TEBs is at least correlative evidence that Ptprb may be suppressing lateral branching 
during ductal elongation, although the TEBs vs ducts study was carried out using C57/Bl6 
mice, rather than FvB, and the possibility of strain-specific differences cannot be definitively 
excluded. Despite this caveat, when considered as a whole the data favour a model in which 
PTPRB is a negative regulator of FGFR-dependent branching, rather than ductal elongation. 
 
PTPRB has been typically characterised as a ‘vascular endothelial-specific’ phosphatase 
(Behjati et al., 2014). However, it is becoming clear that it has a wider role in other tissues. Its 
function in branching morphogenesis in both the vasculature and, as we have now shown, the 
mammary epithelium suggests that PTPRB is a fundamental regulator of this developmental 
program irrespective of organ system. Furthermore, its emerging role in cancer and the 
established importance of the pathway it regulates to tumour biology, reaffirm the relevance of 
developmental signalling programs to the biology of malignant disease.  
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 MATERIALS AND METHODS 
Preparation of mammary epithelial cells for flow cytometry 
All animal work was carried out under UK Home Office project and personal licences 
following local ethical approval by the Institute of Cancer Research Animal Ethics Committee 
and in accordance with local and national guidelines. Single cells were prepared from fourth 
mammary fat pads of virgin female FVB mice as described (Regan et al., 2013) and stained 
with anti-CD24-FITC (clone M/69 at 1.0 µg/ml; BD Biosciences, Oxford, UK; catalogue 
#553261), anti-Sca-1-APC (clone D7 at 1.0 µg/ml; eBioscience, Hatfield, UK; catalogue #17-
5981), anti-CD45-PE-Cy7 (clone 30-F11 at 1.0 µg/ml; BD Biosciences; catalogue #552848), 
anti-CD49f-PE-Cy5 (clone GoH3 at 5.0 µl/ml; BD Biosciences; catalogue #551129) and anti-
c-Kit-PE (clone 2B8 at 1.0 µg/ml; BD Biosciences; catalogue #553355). Mammary epithelial 
cell subpopulations were defined as shown in supplementary material Fig.S1. For sorting of 
GFP+ cells harvested from transplanted fat pads, the combination of anti-CD24-Pacific Blue 
(clone M/69 at 1.0 µg/ml; BD Biosciences, Oxford, UK; catalogue #561079), anti-Sca-1-APC, 
anti-CD45-PE-Cy7 and DAPI was used. DAPI positive dead cells are distinguishable from 
Pacific Blue-stained cells by their very bright fluorescence. 
 
Gene expression analysis by quantitative real-time rtPCR (qPCR) 
Freshly sorted primary cells were lysed in RLT buffer (Qiagen, Crawley, West Sussex, UK) 
and stored at -80oC. Total RNA was extracted using an RNeasy MinElute Kit (Qiagen), 
according to the manufacturers' instructions. For cultured organoids RNA was isolated with 
Trizol (Invitrogen, Paisley, UK). qPCR reactions were performed as previously described using 
either TAQMAN assays or in-house designed probes (supplementary material Table S2) 
(Kendrick et al., 2008). All results were calculated using the Ct method compared to an 
endogenous control gene. Data were expressed as the mean fold gene expression difference in 
three independently isolated cell preparations over a comparator sample with 95% confidence 
intervals. 
 
RNAScope in situ hybridisation for Ptprb 
RNAScope for Ptprb was performed on 5µm sections using RNAscope® 2.5 HD Duplex 
Reagent Kit using manufacturer’s instructions (Advanced Cell Diagnostics, Newark, CA, 
USA). RNAscope® Control Slides -Mouse 3T3 Cell Pellet were used to test the protocol. 
Briefly, sections were cut and left to dry overnight at room temperature. Samples were then 
D
ev
el
o
pm
en
t •
 A
cc
ep
te
d 
m
an
us
cr
ip
t
 baked at 60°C for 1hour, then deparafinisation was performed (2x5min in Fresh Xylene) which 
was followed by 2x1min in 100% ethanol. Sections were then left to dry 5min at room 
temperature. Pretreat1 (H202) was then applied and left 10min at room temperature followed 
by 2 washed in distilled H20. Slides were then left to boil in Pretreat 2 (antigen retrieval) for 
15min and were then washed twice in distilled water (2x5min). Preatreat3 was applied 
(protease) on the slides for 30min at 40°C. After a couple of brief washes in distilled water, 
warmed probes were applied for 2hours at 40°C:  RNAscope® 2-plex Negative Control Probe 
(catalogue # 320751), Mm-Ptprb Cat No. 481391 in C2 channel (red), RNAscope® 2.5 Duplex 
Positive Control Probe (Mm) PPIB-C1 (Green)/POLR2A-C2 (Red). After a couple of washes 
in the wash buffer, slides were left at room temperature overnight in 5XSSC. The next day, 
slides were incubated with several rounds of amplification Amp1-10 reagents following 
manufacturer’s instruction to detect red and green signal. Slides were finally counterstained 5 
seconds in 50% filtered Mayer's Haemalum (Lamb/170D) and washed briefly in water then 
baked for 30min at 60°C. The slides were mounted using Vector Labs Vectamount (60mL) 
(catalogue # 321584). 
 
Isolation of TEB and duct fragments 
Stromal-free terminal end buds (TEB) and ducts were isolated as described previously (Morris 
and Stein, 2017; Morris et al., 2006). Briefly, C57BL/6 mice were humanely killed at 6-7 weeks 
(16-18g) and the inguinal mammary glands were dissected and collected in chilled L15 
medium. 20 glands were pooled for each preparation, coarsely cut with scalpels and digested 
with 1mg/ml (w/v) collagenase Type II (Sigma) at 37°C for 20-30 minutes (for TEB) and 30-
45 min (ducts) with mild agitation. After incubation, the epithelium was further freed of the 
stroma by vigorous shaking by hand. The collagenase was diluted and blocked with fresh cold 
L15 medium with 0.1% FBS and the epithelium spun down at 250g for 5min. The pellet was 
re-suspended in fresh cold L15 medium with 10% FBS, transferred to a gridded 60 mm dish, 
and released TEB and ducts were collected under a stereo dissection microscope with a 10μl 
pipette into 50-100μl TRI-reagent (Sigma) before snap-freezing.  
 
RNA isolation and microarray hybridisation from isolated epithelium 
For RNA isolation, frozen samples were thawed and RNA isolated according to manufacturer’s 
protocol before resuspension in RNase-free water. The RNA was quantified with a Nanodrop 
ND-1000 spectrophotometer, pooled and subjected to on-column DNase I treatment (Qiagen) 
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 and further concentration using a RNeasy-micro kit (Qiagen). RNA quality was finally assessed 
using a 2100 Bioanalyzer and RNA 6000 Nano kit (both Agilent).  
 
For microarray hybridisation, 1.5μg RNA per sample (from ~300-400 isolated TEBs or ducts) 
was used in pooled duplicates and analysed at the Henry Wellcome Functional Genomics 
Facility (Glasgow). rRNA was removed using a RiboMinus Human/MouseTranscriptome 
Isolation kit and RiboMinus magnetic beads, labelled according to manufacturer’s protocol and 
finally hybridised to mouse whole-genome exon arrays (GeneChip-Mouse-Exon-1.0-ST-
Array, Affymetrix UK Ltd., High Wycombe, UK) using a GeneChip Fluidics Station 450/250. 
The signals were measured using a GeneChip Scanner 3000 7G. CEL-files were analysed and 
normalised by RMA using the open-source ‘Altanalyze’ software (Emig et al., 2010). Results 
of differentially abundant RNAs in TEB and ducts were ranked according to raw p-value (one-
way analysis of variance (ANOVA)) (Table S1). Raw data files have been submitted to GEO 
with the accession number GSE94371. 
 
Lentivirus production 
Oligonucleotide pairs for shPtprb#1 (CACCGCGTCACCCTGTAACTTTAGCCGAA 
GCTAAAGTTACAGGGTGACGC and AAAAGCGTCACCCTGTAACTTTAGCTTCGGC 
TAAAGTTACAGGGTGACGC) and shPtprb#2 (CACCGCAAACACCTCCTTGGCTATCC 
GAAGATAGCCAAGGAGGTGTTTGC and AAAAGCAAACACCTCCTTGGCTATCTT 
CGGATAGCCAAGGAGGTGTTTGC) were ligated into pENTR/U6 Gateway system entry 
vector (Invitrogen, Paisley, UK) according to manufacturer’s instructions. Hairpin sequences 
were verified and then transferred, together with the U6 promoter, into a Gateway-modified 
pSEW lentiviral vector backbone (Vafaizadeh et al., 2010) by LR reaction (Invitrogen). Viral 
supernatants were generated by Lipofectamine 2000 (Invitrogen, #11668-019) co-transfection 
of the packaging and viral DNA sequence plasmids into HEK293T cells. Cells were re-fed with 
fresh medium (Dulbecco’s Modified Eagle’s Medium, DMEM; Invitrogen) plus 10% FCS 
(PAA Laboratories, GE Healthcare, Amersham, UK) after 24 hours. Supernatants were 
harvested 48 and 72 hours after transfection and assayed for absence of replication-competent 
virus. Supernatants were stored at -80oC until use. For transplantation assays, primary 
mammary cells were transduced with lentivirus using the suspension method as described 
(Kendrick et al., 2008). Supernatants were adjusted by dilution where necessary to ensure 
comparable viral titres prior to transduction. 
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 Mammary epithelial cell transplantation 
Transplantation of lentivirus-transduced primary FVB mouse mammary epithelial cells into 
cleared fats pads of athymic Ncr Nude mice was carried out as described (Britt et al., 2009, 
Sleeman et al., 2007). Fat pads were harvested 8 weeks after transplantation, wholemounted 
and photographed under epifluorescent illumination. For size analysis, the area of the GFP+ 
outgrowths (defined by a continuous line around the outermost limit of the outgrowth) was 
determined using ImageJ with reference to a scale bar. For branching analysis, the number of 
branch points was counted in three 0.1cm2 fields per view per gland. The small size and 
difficulty in obtaining clear images of some outgrowths meant that not all of the outgrowths 
analysed for size were available for branching analysis. 
 
Mice were injected with control and knockdown cells in contralateral fat pads (shLuc vs 
shPtprb pool; shScr1 vs shPtprb 0145; shScr1 vs shPtprb 3820) to control for variability in 
growth between animals and variability in time at which glands were harvested, both of which 
will affect the size of the final outgrowth. 
 
For flow sorting analysis, GFP+ outgrowths were dissected out and processed to single cells, 
stained and analysed as described above. For secondary transplantation, GFP+ outgrowths 
were dissected out, processed to single cells and immediately re-transplanted. For histological 
analysis of transplants, small (5 mm3) pieces of GFP+ outgrowths were dissected out, formalin-
fixed and paraffin embedded by standard methods. Dewaxed and re-hydrated sections 
underwent antigen retrieval in citrate buffer (0.01M, pH 6.0) for 18 min in a microwave (900W) 
before blocking in DAKO REAL Peroxidase blocking solution for 10 minutes (Dako UK Ltd, 
Cambridgeshire, UK) for 30 min. Sections were incubated in Mouse on Mouse (M.O.M) 
Mouse Ig blocking reagent (Vector Laboratories, Peterborough, UK #BMK-2202) for 60 
minutes followed by primary antibody for 60 minutes at room temperature, followed by M.O.M 
Biotinylated Anti-mouse IgG Reagent for 10 minutes. The secondary antibody was detected 
by application of Vectastain Elite ABC reagent for 5 minutes followed by application of the 
chromogen 3,3'-Diaminobenzidine (DAB) for 5 minutes (ABC, Vector Laboratories). Primary 
antibodies used were anti-K8/18 (clone Ks18.04, mouse monoclonal, catalogue #61028, 
Progen Biotechnik, Heidelberg, Germany; diluted 1:2), anti-SMA (clone 1A4, mouse 
monoclonal, catalogue #A5691, Sigma, UK; diluted 1:500).  
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 For Immunofluorescence, sections were incubated in Mouse on Mouse (M.O.M) Mouse Ig 
blocking reagent for 60 minutes, followed by overnight incubation in primary antibody at 4oC. 
Primary antibody was detected with an appropriate Alexafluor-conjugated secondary antibody. 
Images of stained sections were captured using a Leica TCS-SP2 microscope in three or four 
channels using Leica LCS software (Leica Microsystems, Milton Keynes, UK). Negative 
controls were performed using the same protocols with substitution of the primary antibody 
with IgG matched controls. In double staining experiments, control single stained sections in 
which either the primary antibody was left out or the primary antibody was combined with the 
wrong secondary antibody showed no staining. Primary antibodies used were, anti-SMA (clone 
1A4, mouse monoclonal, catalogue #A5691, Sigma, UK; diluted 1:500), anti-Ki67 (rabbit 
polyclonal, catalogue #ab16667, Abcam, UK; diluted 1:300), anti- cleaved caspase-3 (rabbit 
polyclonal, catalogue #9661S, Cell signalling, UK; diluted 1:100). Lung tissue from mice 
treated with four doses of doxorubicin at 2.5mg kg-1 and cyclophosphamide at 40mg kg-1 at 
five day intervals and then harvested five days after the final dose was used a positive control 
for cleaved caspase-3. 
 
Isolation and culture of mammary gland organoids 
Cultures were prepared as previously described (Ewald et al., 2008; Fata et al., 2007). Briefly, 
third and fourth mammary fat pad pairs were harvested virgin female 8-10 week old FVBn 
mice. Fat pads were minced and tissue shaken for 30-45 minutes at 37oC in 50 ml 1:1 
DMEM:Ham's F12 (Invitrogen), 5% FCS (PAA Laboratories) media with 3 mg/ml collagenase 
A (Roche Life Sciences, West Sussex, UK) and 3 mg/ml trypsin (Sigma). The collagenase 
solution was centrifuged at 1500 rpm for 10 min, dispersed through 10 ml 1:1 DMEM:Ham’s 
F12, centrifuged at 1500 rpm for 10 min, and then resuspended in  5 ml 1 μg/ml DNase I 
(Sigma) in serum free 1:1 DMEM:Ham's F12 medium. The DNase solution was shaken by 
hand at room temperature for 2-5 minutes then centrifuged at 1500 rpm for 10 min. Organoids 
were separated from single cells through four differential centrifugations (pulse to 1500 rpm in 
10 ml 1:1 DMEM:Ham’s F12). The final pellet was re-suspended in the desired amount of 
Growth Factor Reduced Matrigel (BD Biosciences) or 1:1 mix of Growth Factor Reduced 
Matrigel and lentivirus or 1:1 DMEM:Ham’s F12 for non-infected controls. 
 
Organoid assays were carried out in 24-well plates. 50 μl of cold Growth Factor Reduced 
Matrigel was laid onto a sterile 13 mm diameter borosilicate glass coverslip and incubated for 
30 minutes at 37oC to solidify. 50μl of the organoid and Matrigel mix or organoid, Matrigel 
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 and lentivirus mix was plated over the solidified Matrigel and the plate incubated at 37oC for 
another 30 minutes. Once the Matrigel or 1:1 Matrigel:lentivirus mix containing the organoids 
had set, the organoids were covered with minimal media (1:1 DMEM:Ham's F12, 5ug/ml 
insulin (Sigma) or branching medium (minimal medium + 50ng ml-1 FGF2 (Peprotech, 
London, UK). ANG1 and ANG2 were a kind gift of Dr Andy Reynolds (Institute of Cancer 
Research, London, UK) and were also added at 50ng ml-1). For lentiviral transduction 
experiments, organoids with a minimum of ≥30% GFP positive cells were analysed, in line 
with previous studies (Macias et al., 2011). 
 
Protein analysis 
Transduced mammary organoids were serum starved for 12 hours and left unstimulated or 
stimulated with 10 ng/ml FGF2 for the indicated times. ERK1/2 inhibitor SCH772984 was 
obtained from Selleckchem (Newmarket, Suffolk, UK; #S7101). Organoids were released from 
Matrigel using non-enzymatic cell recovery solution (BD Biosciences) and then lysed in 
Laemmli buffer (2% SDS, 10% glycerol, 1.25% beta-mercaptoethanol, 0.002% bromphenol 
blue, 0.0625 M Tris pH 6.8). Following SDS-PAGE, protein extracts were transferred to a 
PVDF membrane and probed with antibodies to p44/42 MAPK (ERK1/2) (Cell Signalling 
Technologies, Leiden, The Netherlands, Antibody #9102), phospho-p44/42 MAPK (ERK1/2) 
(Thr202/Tyr204) (Cell Signalling Technologies, Antibody #9101), phospho-FGF Receptor 
(Tyr653/654) (Cell Signalling Technologies, Antibody #3471), FGFR1 (9740, Cell Signaling, 
Technology, Rabbit monoclonal, clone D8E4), FGFR2 (H00002263-M01, Abnova,  Mouse 
monoclonal, clone 1G3), FGFR3 (PA5-34574, Rabbit polyclonal, ThermoFisher Scientific), 
FGFR4 (HPA028251, Rabbit polyclonal, Sigma Aldrich) or anti-tubulin (clone BM1A), 
Sigma, antibody #T6199). After incubation with peroxidase-conjugated secondary antibodies, 
immunocomplexes were detected using Enhanced Chemiluminescent (ECL) reagents. 
Densitometric analysis was performed using Image J software. 
 
Statistics 
Significance of gene expression differences analysed by qrtPCR were determined using 95% 
confidence intervals as described (Cumming et al., 2007). To test whether Ptprb knockdown 
decreased size of outgrowths but increased branching, one-tailed unpaired t-tests were used. 
To determine whether Ptprb knockdown increased levels of ERK1/2 and FGFR 
phosphorylation in response to FGF2 stimulation, one-tailed unpaired t-tests were used. To 
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 determine differences in organoid branching, Chi2 test of distribution of categorical variables 
was used. 
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 Fig.1. Ptprb expression is repressed in mid-pubertal mammary epithelial cells. (A) 
Wholemounted fourth mammary fat pads from FVB mice at 3-4, 5-6 and 8-10 weeks old 
illustrating the extent of ductal developement. Bar = 3 mm. Magnified region of 3-4 week fat 
pad to show terminal end buds is enlarged 5x. (B) Relative Ptprb expression between MaSCs 
and MYO, MaSCs and LumER- and MaSCs and LumER+ populations (indicated by bars) 
determined by qPCR at three timepoints. The comparator sample is the LumER- population at 
each age group. **P<0.01, *P<0.05, N.S., not significant. (C) Relative Ptprb expression within 
each population across the three timepoints. Comparator was the 4-week-old sample for each 
population. Significance comparisons between 4-week and 6-week, 4-week and 8-week and 
between 6-week and 8-week populations indicated by bars. **P<0.01, *P<0.05, N.S., not 
significant. Data in (B) and (C) were from three independent isolates of each cell population at 
each age. Data were normalised to β-actin and expressed as mean log10 relative fold expression 
(±95% confidence intervals) over the comparator.  
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Fig.2. Ptprb knockdown promotes branching morphogenesis in vivo. (A) qPCR analysis of 
Ptprb gene expression in non-transduced primary mouse mammary epithelial cells and in cells 
transduced with either an empty virus, a control virus carrying a scrambled oligo sequence 
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 (shScr), a sequence targeting Luciferase (shLuc), or a virus pool consisting of two viruses 
(shPtprb 0145 and 3820) targeting Ptprb. (B) qPCR analysis of Ptprb gene expression in non-
transduced cells and cells transduced with shScr virus or the individual shPtprb 0145 and 
shPtprb 3820 viruses. Data in (A,B) presented as mean fold Ptprb expression (±95% 
confidence intervals; n=3 independent experiments) over comparator (non-transduced cells). 
*P<0.05 compared to non-transduced cells; **P<0.01 compared to non-transduced cells; 
##P<0.01 compared to shLuc or shScr transduced cells. (C) Representative images of GFP+ 
outgrowths in wholemounted fat pads eight weeks after transplant of control- or shPtprb-
transduced cells. Scale bar = 5 mm. Insets are magnified x3. Branch points in insets are 
indicated by arrowheads. For each shPtprb fat pad, the control shown next to it is a transplanted 
contralateral gland from the same animal. (D,E) Analysis of size (D) and branching (E) of 
control and shPtprb knockdown outgrowths (means±SEM). *P<0.05, **P<0.01, ***P<0.001. 
shLuc and shPtprb data from two independent transplant experiments; shScr, shPtprb 0145 and 
shPtprb 3820 data from three independent experiments. Numbers of fat pads analysed are 
provided in supplementary material Fig.S4A. 
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Fig.3. Ptprb knockdown increases mammary epithelial cell proliferation. (A, B) Staining 
of sections of shLuc (top rows) and shPtprb (bottom rows) outgrowths with anti-SMA and 
DAPI and either anti-K18 (A) or anti-Ki67 (B) antibodies. Scale bars = 100 μm. (C) 
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 Quantitation of Ki67 staining in luminal (SMA-) and basal (SMA+) layers of shPtprb 
outgrowths. Data shown as mean±SEM (n=8 regions from three independent control 
outgrowths and 11 regions from three independent Ptprb-knockdown outgrowths). (D) 
Analysis of areas (mm2) of outgrowths of shScr (n=8) and shPtprb 0145 (n=8) secondary 
transplants (mean±SEM). *P<0.05. 
  
D
ev
el
o
pm
en
t •
 A
cc
ep
te
d 
m
an
us
cr
ip
t
  
Fig.4. Ptprb knockdown promotes branching morphogenesis in an in vitro model system. 
Non-infected (NI), shScr, shPtprb 0145 and shPtprb 3820 transduced organoids were 
embedded in Matrigel and stimulated to branch with FGF2 for five days in culture. Data from 
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 three independent experiments (duplicate wells for each treatment per experiment). GFP 
expression was used as a marker of lentivirus infection. A) Number of branched organoids as 
a percentage of the total number of organoids (mean±SD). *P<0.05 (t-test). B) Representative 
images of organoids with no branching (0 branches), low-level branching (1-5 branches), 
intermediate-level branching (6-15) and high-level branching (>15) Scale bar = 30μm. Merged 
GFP-fluorescence and phase contrast images. C) Extent of branching in non-infected (NI), 
shScr and Ptprb knockdown organoids. The proportion of organoids with low, intermediate or 
high level branching is shown as a percentage of the total number of branched organoids per 
treatment. *P<0.05; **P<0.01 (Chi2 test of distribution of categorical variables). 
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Fig.5. FGF2 suppresses Ptprb expression in vitro. (A) Representative images of 
unmanipulated organoids in 3D culture either ‘non-stimulated’ (without growth factor; top 
panel) or ‘stimulated’ (with FGF2; bottom panel). Scale bars = 100 m. Arrowheads indicate 
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 branches emerging at day 4. Asterisks indicate organoids magnified 2.5 times in inset panels. 
B, C) Ptprb expression in non-stimulated and stimulated organoids, taken at 24 hour time 
points for 6 days, determined by qPCR. Data normalised to β-actin and expressed as mean 
log10 relative fold expression (±95% confidence intervals) over comparator population. Data 
collected from three independent organoid preparations. (B) Ptprb expression in stimulated 
organoids using the day 0 time point as the comparator sample. **P<0.01 compared to day 0; 
#P<0.01 compared to day 2 (t-tests). (C) Ptprb expression in non-stimulated and stimulated 
organoids with expression levels in stimulated organoids compared to non-stimulated 
organoids at the same time point. **P<0.01 relative to comparator. 
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Fig.6. Analysis of expression of candidate PTPRB-interacting receptor tyrosine kinases 
in mammary epithelial subpopulations. (A) Relative Ptprb, Fgfr2, Tek, Egfr, Fgfr1 and Igfr1 
expression in MaSCs MYOs, LumER- and LumER+ populations determined by qPCR at mid-
puberty (5 – 6 week samples). The comparator sample is the LumER- population in all cases. 
Ptprb data reproduced from Fig. 1 for reference. **P<0.01 vs LumER-, *P<0.05 vs LumER- ; 
##P<0.01 vs MYO, #P<0.05 vs MYO; ^^P<0.01 vs LumER+, ^P<0.05 vs LumER+. For 
simplicity, significance is only shown compared to lower expressing samples. (B,C) Relative 
Ptprb, Fgfr2 and Tek expression in LumER+ cells (B) and MaSCs (C) at 3-4, 5-6 and 8-10 
weeks of age. The comparator was the 4-week-old sample for each population. Data were 
normalised to β-actin and expressed as mean log10 relative fold expression (±95% confidence 
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 intervals) over the comparator. Data from three independent isolates of each cell population at 
each age. Ptprb data reproduced from Fig. 1 for reference. **P<0.01 vs 3-4 week samples, 
*P<0.05 vs 3-4 week samples. 
  
D
ev
el
o
pm
en
t •
 A
cc
ep
te
d 
m
an
us
cr
ip
t
  
Fig.7. PTPRB suppresses FGFR2 signalling by negatively regulating ERK1/2. (A,B) 
Western blot analysis of phospho-FGFR levels (A) and phospho- and total-ERK1/2 levels (B) 
in shLuc-, shPtprb 0145- and shPtprb 3820-transduced primary mouse organoid cultures either 
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 unstimulated or stimulated with FGF2 for 5, 15 and 60 minutes. Blots are representative of 
three independent experiments; quantitation of phospho:total ERK1/2 ratios and phospho-
FGFR:tubulin loading control ratios are shown below the blots (mean±SEM). *indicates a 
significant (P<0.05) increase over the shLuc control at that timepoint. The original blots are 
show in supplementary material Figs. S6 and S11. (C) Extent of branching in bFGF-stimulated 
shScr-organoids (Scr) and Ptprb knocked-down organoids (0145 and 3820) stimulated with 
bFGF and treated or not with SCH772984 (2 nM). *P<0.05; ***P<0.01 vs control FGF-
stimulated samples (Chi2 test of distribution of categorical variables). 
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Development 144: doi:10.1242/dev.149120: Supplementary information
Fig. S1. Flow cytometry gating workflow for isolation of mammary epithelial 
subpopulations. (A) Gating workflow demonstrating identification of single cells by time-of-
flight analysis on forward and then side scatter, followed by exclusion of DAPI+ dead cells 
and CD45+ white blood cells. Remaining cells are then plotted on a Sca-1 vs CD24 plot and 
the epithelial cells gated as described (Britt et al., 2009). This sorting strategy isolates all 
mammary epithelial cells (Britt et al., 2009). The epithelial-only population is then analysed in 
two ways. First, it is plotted on a Sca-1 vs CD24 dot plot and the luminal ER+ and luminal ER- 
populations gated, with c-Kit staining of the latter being further assessed to identify the c-Kit+ 
progenitors. Second, the epithelial population is plotted on a CD24 vs CD49f contour plot 
(linear density, 5% intervals) to identify the MYOs and MaSCs, as previously described in 
detail (Britt et al., 2009; Soady et al., 2015). MASCs, MYOs, Luminal ER- and Luminal ER+ 
cells, as gated, collectively form >90% of the total mammary epithelium (Regan et al., 2012). 
(B) Control plots showing samples in which either only DAPI was added (left, middle) or in 
which the anti-c-Kit-PE was omitted (right). 
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Development 144: doi:10.1242/dev.149120: Supplementary information
Fig. S2. Ptprb localisation by RNAScope 2.5 HD Duplex in situ hybridisation. Red label 
indicates a positive signal. ‘Neg’ indicates samples labelled with the negative control probe. 
‘Ptprb’ indicates samples labelled with the Ptprb probe. ‘bv’ indicates a blood vessel, ‘ed’ 
epithelial duct. Bars = 50µm. Top row, liver (left two panels) used as positive control tissue, 
and sections from 3 week old mammary gland (right two panels). A strong, uniform Ptprb 
signal was detected on the endothelial cells lining blood vessels (middle right panel) and a 
positive signal was also detected in a subset of cells lining epithelial ducts (far right panel). 
Middle row, 6 week old mammary gland, showing a strong Ptprb signal on blood vessels 
(left two panels, white arrows on inset) and a signal on stromal cells surrounding the 
epithelial ducts (right panels, white arrows on inset) but no signal could be detected in the 
epithelium. Note that the positioning of distinctive elongated myoepithelial nuclei (black 
arrows on inset) demonstrate that the labelled cells are indeed outside the ducts. Bottom row, 
12 week old mammary gland, again showing a strong Ptprb signal on blood vessels (left two 
panels) and a weak positive signal in a subset of cells lining epithelial ducts (right two panels, 
arrowheads on inset). 
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Development 144: doi:10.1242/dev.149120: Supplementary information
Fig. S3. Ptprb knockdown does not alter proportions of cell populations in vitro. (A) 
Representative flow cytometry plots form analysis of cells recovered from transplanted 
mammary fat pads. Only the epithelial populations are shown. Epithelial outgrowths from viral 
transplants consist of both transduced (GFP positive) and non-transduced cells (GFP negative) 
and both of these include basal, LumER- and LumER+ populations, defined by CD24 and Sca- 
1 expression patterns (Soady et al., 2015). Top, analysis of fat pads carrying non-transduced 
cells. Middle, analysis of shScr-transduced transplants. Bottom, analysis of sh Ptprb 0145-
transduced transplants. (B) Proportions of basal, luminal ER negative and luminal ER positive 
cell populations in GFP+ (viral-transduced) cells harvested from fat pads transplanted with 
primary mammary epithelial cells transduced with shScr, shPtprb 0145 or shPtprb 3820. Data 
presented as mean proportion of total epithelial cells ± SD. n indicates number of independent 
transplant experiments, each of which included at least five transplanted fat pads, which 
contributed to the data. There are no differences between the proportions of the populations in 
the control compared to the knockdown transplants. 
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Development 144: doi:10.1242/dev.149120: Supplementary information
Fig. S4. Ptprb knockdown does not enhance apoptosis. (A) Numbers of transplanted fat 
pads used to determine the size of outgrowths from knockdown and control cells and the 
amount of branching. (B) Cleaved Caspase-3 / DAPI staining of shLuc and shPtprb 
transplants, together with positive control lung tissue sample (Ctx, chemotherapy-treated). 
Bar = 100 m. (C) Wholemounts of fat pads from secondary transplants of shScr (top) and 
shPtprb 0145 (bottom) transduced cells. Bars = 5 mm. 
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Development 144: doi:10.1242/dev.149120: Supplementary information
Fig. S5. In vitro organoid branching is dependent on FGF2. (A) Transduction with shLuc, 
shPtprb 0145 or shPtprb 3820 in the absence of FGF2 stimulation does not cause branching. 
High levels of sh lentiviral transduction are indicated by strong GFP expression. Images are 
representative of multiple independent wells from three indpendent experiments. Paired 
phase contrast and GFP pictures are shown. Scale bars = 30 m. (B) Examples of untreated 
organoids and organoids treated for seven days with 50 ng ml-1 FGF2, ANG1 or ANG2. 
Branching of organoids is only seen in FGF2 stimulated cultures. Images are representative 
of multiple independent wells from three independent experiments. Scale bars = 30 m. 
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Development 144: doi:10.1242/dev.149120: Supplementary information
Fig. S6. Ptprb knockdown enhances FGFR phosphorylation. Raw western blot data of 
effects of Ptprb knockdown on FGFR phosphorylation in response to FGF2 stimulation. Films 
of blots probed for phospho FGFR and TUBULIN are shown (blots used for preparing Figure 
7A). ‘Sh1’ and ‘1’ indicate sh Ptprb 0145. ‘Sh2’ and ‘2’ indicate sh Ptprb 3820. 
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Development 144: doi:10.1242/dev.149120: Supplementary information
Fig. S7. Ptprb knockdown does not alter total FGFR levels. (A) Western blot analysis of total 
FGFR1, 2, 3 and 4 levels in organoid cultures transduced with control, 0145 or 3820 
knockdown lentiviruses and either unstimulated or stimulated with FGF2. (B) Quantitation 
of total FGFR levels (mean ±SD; n=3). 
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Development 144: doi:10.1242/dev.149120: Supplementary information
Fig. S8. Ptprb knockdown does not alter total FGFR levels. Raw western blot data of total 
FGFR1, 2, 3 and 4 levels in organoid cultures transduced with control, 0145 or 3820 
knockdown lentiviruses and either unstimulated or stimulated with FGF2 (blots used 
for preparing Supplementary Figure S7). 
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Development 144: doi:10.1242/dev.149120: Supplementary information
Fig. S9. ERK1/2 inhibition blocks bFGF-induced mammary branching. (A) Western blot 
analysis of phospho- and total ERK1/2 levels in organoid cultures either unstimulated or 
stimulated with FGF2 and treated with High (8 nM),  Medium (4 nM) or Low (2 nM) 
concentration of SCH772984. Tubulin was used as loading control. (Bi - Bv) Representative 
images of organoids at day 8 of culture. 
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Development 144: doi:10.1242/dev.149120: Supplementary information
Fig. S10. ERK1/2 inhibition blocks bFGF-induced mammary branching. Raw western 
blot data of effects of SCH772984 treatment on phospho- and total ERK1/2 in response to 
FGF2 stimulation. Blots probed for pERK1/2, tubulin and pFGFR (top blot, short exposure; 
middle blot, long exposure) and for total ERK1/2 (bottom blot). Blots used for preparing 
Supplementary Figure S9. 
D
ev
el
o
pm
en
t •
 S
up
pl
em
en
ta
ry
 in
fo
rm
at
io
n
Development 144: doi:10.1242/dev.149120: Supplementary information
Fig. S11. Ptprb knockdown enhances ERK1/2 phosphorylation. Raw western blot data of 
effects of Ptprb knockdown on ERK1/2 phosphorylation in response to FGF2 stimulation. 
Films of representative blots probed for total ERK1/2, phospho ERK1/2 and GAPDH are 
shown (blots used for preparing Figure 7B). 
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Gene
Actb
Egfr
Erbb2
Fgfr1
Fgfr2
Igf1r
Unigene TAQMan Assay
Mm.391967 Mm00607939_s1
Mm. 8534 Mm00433023_m1
Mm. 290822 Mm00658541_m1
Mm. 265716 Mm00438930_m1
Mm. 16340 Mm00438941_m1
Mm. 275742 Mm00802831_m1
Gene
Actb
Unigene Sybr Green probes
Mm.391967 Fwd: agcgcaagtactctgtgtgga
Ptprb
Rev: gggccggactcatcgtact
Mm.37213 Fwd: acatttatggggcagtgcat
Rev: gttccgcagtttctttgctc
Tek/Tie2 Mm.14313 Fwd: gacagtgctggagggagaag
Rev: tccgcagagcagtcaattc
SUPPLEMENTARY TABLES 
Table S1. Gene expression analysis comparing isolated TEBs vs ductal fragments. Data 
for 3756 genes with >1.5 fold differential expression between the two structures from two 
independent replicates each of which analysed TEBs and duct fragments from >100 animals.  
Table S2. Sybr green probes and TAQMan assays for quantitative real-time rtrPCR. 
Click here to Download Table S1
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